Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says

Executive Summary

Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.


Related Content

Congress Can Find Consensus On Drug Pricing By Targeting Cost Drivers – Waxman
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
Gottlieb Talks Activist Role For FDA In Curbing REMS Abuse
After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts